CAPOCEFALO, Antonio
 Distribuzione geografica
Continente #
NA - Nord America 477
EU - Europa 413
AS - Asia 176
AF - Africa 1
Continente sconosciuto - Info sul continente non disponibili 1
Totale 1.068
Nazione #
US - Stati Uniti d'America 463
CN - Cina 135
FI - Finlandia 103
IE - Irlanda 95
SE - Svezia 70
UA - Ucraina 50
DE - Germania 41
TR - Turchia 26
IT - Italia 20
SG - Singapore 13
AT - Austria 12
BE - Belgio 12
CA - Canada 12
GB - Regno Unito 8
BZ - Belize 2
FR - Francia 2
CI - Costa d'Avorio 1
EU - Europa 1
IN - India 1
VN - Vietnam 1
Totale 1.068
Città #
Dublin 95
Chandler 78
Jacksonville 72
New York 36
Ann Arbor 33
Dearborn 33
Shanghai 29
Beijing 22
Ashburn 21
Izmir 21
Nanjing 21
Princeton 17
San Mateo 15
Wilmington 13
Brussels 12
Toronto 12
Vienna 12
Düsseldorf 9
Nanchang 9
Hefei 8
Kunming 8
Des Moines 7
Falls Church 7
Helsinki 7
Parma 7
Singapore 7
Boardman 6
Hebei 6
Jinan 5
Kocaeli 5
Norwalk 5
Shenyang 5
Bremen 3
London 3
Seattle 3
Belize City 2
Buffalo 2
Casalpusterlengo 2
Changsha 2
Chicago 2
Hanover 2
Jiaxing 2
Mestre 2
Milan 2
Rockville 2
Rome 2
San Jose 2
Tianjin 2
Woodbridge 2
Zhengzhou 2
Abidjan 1
Albuquerque 1
Bologna 1
Chengdu 1
Guangzhou 1
Haikou 1
Houston 1
Leawood 1
Ningbo 1
Reggio Nell'emilia 1
Simi Valley 1
Taiyuan 1
Wenzhou 1
Wuhan 1
Xian 1
Totale 697
Nome #
Swine adipose stromal cells loaded with recombinant bovine herpesvirus 4 virions expressing a foreign antigen induce potent humoral immune responses in pigs. 101
Virally and physically transgenized equine adipose-derived stromal cells as a cargo for paracrine secreted factors 87
Double immunization strategy with a BoHV-4-vectorialized secreted chimeric peptide BVDV-E2/BoHV-1-gD 80
Bovine herpesvirus 4 immediate early 2 (Rta) gene is an essential gene and is duplicated in bovine herpesvirus 4 isolate U. 74
Cellular targeting of engineered heterologous antigens is a determinant factor for bovine herpesvirus 4- based vaccine vector development 73
BoHV-4 immediate early 1 gene is a dispensable gene and its product is not a bone marrow stromal cell antigen 2 counteracting factor 70
Immunization of knock-out α/β interferon receptor mice against lethal bluetongue infection with a BoHV-4-based vector expressing BTV-8 VP2 antigen. 69
In VivoImaging of Transiently Transgenized Mice with aBovine Interleukin 8 (CXCL8) Promoter/LuciferaseReporter Construct 61
The Chemokine IL8 Is Up-Regulated in Bovine Endometrial Stromal Cells by the BoHV-4 IE2 Gene Product, ORF50/Rta: A Step Ahead Toward a Mechanism for BoHV-4 Induced Endometritis. 58
p21Waf1/Cip1 as a molecular sensor for BoHV-4 replication 54
Expression and secretion of Bluetongue virus serotype 8 (BTV-8)VP2 outer capsid protein by mammalian cells. 53
Bacterial infection of endometrial stromal cells influences bovine herpesvirus 4 immediate early gene activation: a new insight into bacterial and viral interaction for uterine disease. 52
Isolation and characterization of bovine herpesvirus 4 (BoHV-4) from a cow affected by post partum metritis and cloning of the genome as a bacterial artificial chromosome. 51
Herpes simplex virus type 1 thymidine kinase-armed bovine herpesvirus type 4-based vector displays enhanced oncolytic properties in immunocompetent orthotopic syngenic mouse and rat glioma models. 50
Integration of bovine herpesvirus 4 genome into cultured persistently infected host cell genome. 49
Bovine herpesvirus 4 glycoprotein B is indispensable for lytic replication and irreplaceable by VSVg. 49
Efficient heterologous antigen gene delivery and expression by a replication-attenuated BoHV-4-based vaccine vector 47
Totale 1.078
Categoria #
all - tutte 3.808
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 3.808


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020233 40 37 18 2 18 28 30 1 19 17 4 19
2020/2021108 0 15 9 1 14 1 18 1 22 8 18 1
2021/202294 2 0 1 4 6 7 15 11 7 13 1 27
2022/2023326 34 39 23 25 23 36 3 20 116 0 3 4
2023/2024134 9 11 5 2 8 51 12 10 3 0 7 16
2024/20253 3 0 0 0 0 0 0 0 0 0 0 0
Totale 1.078